[go: up one dir, main page]

MX2018008449A - Tratamiento de eccema de las manos. - Google Patents

Tratamiento de eccema de las manos.

Info

Publication number
MX2018008449A
MX2018008449A MX2018008449A MX2018008449A MX2018008449A MX 2018008449 A MX2018008449 A MX 2018008449A MX 2018008449 A MX2018008449 A MX 2018008449A MX 2018008449 A MX2018008449 A MX 2018008449A MX 2018008449 A MX2018008449 A MX 2018008449A
Authority
MX
Mexico
Prior art keywords
treatment
eccema
hands
oxopropanenitrile
octan
Prior art date
Application number
MX2018008449A
Other languages
English (en)
Other versions
MX394358B (es
Inventor
Wennberg Tero
Per Sørensen Anders
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55236207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018008449(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of MX2018008449A publication Critical patent/MX2018008449A/es
Publication of MX394358B publication Critical patent/MX394358B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Storage Of Fruits Or Vegetables (AREA)

Abstract

La presente invención se refiere al tratamiento del eccema de las manos. El problema que va a ser resuelto por la invención es proporcionar un nuevo uso farmacéutico del 3-[(3S,4R)-3-metil-6-(7 H-pirrolo[2,3-d]pirimidin-4-il)-1,6-diazaespiro[3,4]octan-1-il]-3 -oxopropanonitrilo. La invención también se refiere a un agente terapéutico o preventivo para el eccema de las manos, que contiene el 3-[(3S,4R)-3-metil-6-(7H-pirrolo[2,3-d]pirimidin-4-il) -1,6-diazaespiro[3,4]octan-1-il]-3-oxopropanonitrilo como un ingrediente activo.
MX2018008449A 2016-01-21 2017-01-20 Tratamiento de eccema de las manos. MX394358B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16152215 2016-01-21
PCT/EP2017/051133 WO2017125523A1 (en) 2016-01-21 2017-01-20 Treatment of hand eczema

Publications (2)

Publication Number Publication Date
MX2018008449A true MX2018008449A (es) 2018-08-09
MX394358B MX394358B (es) 2025-03-24

Family

ID=55236207

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018008449A MX394358B (es) 2016-01-21 2017-01-20 Tratamiento de eccema de las manos.
MX2022005915A MX2022005915A (es) 2016-01-21 2018-07-09 Tratamiento de eccema de las manos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022005915A MX2022005915A (es) 2016-01-21 2018-07-09 Tratamiento de eccema de las manos.

Country Status (30)

Country Link
US (2) US20200397787A1 (es)
EP (2) EP3405197B1 (es)
JP (1) JP6929860B2 (es)
KR (2) KR20250088666A (es)
CN (3) CN108472297A (es)
AU (3) AU2017209932A1 (es)
BR (1) BR112018014769A2 (es)
CA (1) CA3010547A1 (es)
DK (1) DK3405197T3 (es)
ES (1) ES2963784T3 (es)
FI (2) FI3405197T3 (es)
FR (1) FR24C1053I2 (es)
HR (1) HRP20231448T1 (es)
HU (2) HUE064192T2 (es)
IL (4) IL313543A (es)
LT (2) LT3405197T (es)
MX (2) MX394358B (es)
NL (1) NL301306I2 (es)
NO (1) NO2024058I1 (es)
PL (1) PL3405197T3 (es)
PT (1) PT3405197T (es)
RS (1) RS64798B1 (es)
RU (1) RU2018130097A (es)
SG (2) SG11201805394QA (es)
SI (1) SI3405197T1 (es)
SM (1) SMT202300415T1 (es)
TW (2) TWI841027B (es)
UA (1) UA123780C2 (es)
WO (1) WO2017125523A1 (es)
ZA (1) ZA201804098B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3968997A1 (en) * 2019-05-15 2022-03-23 Leo Pharma A/S Treatment of cutaneous lupus erythematosus
EP4288058A1 (en) * 2021-02-02 2023-12-13 Pfizer Inc. Dosing regime for treatment of chronic hand eczema
CN117729924A (zh) * 2021-07-30 2024-03-19 伊莱利利公司 用巴瑞克替尼治疗手部湿疹
AU2024238918A1 (en) 2023-03-17 2025-10-09 Leo Pharma A/S A method for the treatment of chronic hand eczema in patients with moderate to severe chronic hand eczema

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
US20130302298A1 (en) * 2010-11-30 2013-11-14 Bio-K Plus International Inc. Treatment and prevention of eczema
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent

Also Published As

Publication number Publication date
PL3405197T3 (pl) 2024-02-12
LT3405197T (lt) 2023-11-27
SG11201805394QA (en) 2018-08-30
TWI783921B (zh) 2022-11-21
IL297379A (en) 2022-12-01
ES2963784T3 (es) 2024-04-02
NO2024058I1 (no) 2024-12-13
NZ743582A (en) 2024-12-20
MX2022005915A (es) 2022-06-27
MX394358B (es) 2025-03-24
NL301306I2 (nl) 2024-12-30
IL260094A (en) 2018-07-31
HRP20231448T1 (hr) 2024-03-01
RU2018130097A (ru) 2020-02-21
ZA201804098B (en) 2024-10-30
SI3405197T1 (sl) 2024-03-29
AU2022252766B2 (en) 2024-08-29
EP3405197B1 (en) 2023-09-06
FI3405197T3 (fi) 2023-11-23
IL313543A (en) 2024-08-01
WO2017125523A1 (en) 2017-07-27
TW202332451A (zh) 2023-08-16
UA123780C2 (uk) 2021-06-02
AU2022252766A1 (en) 2022-11-03
CA3010547A1 (en) 2017-07-27
IL320757A (en) 2025-07-01
US20230138114A1 (en) 2023-05-04
LTPA2024538I1 (es) 2025-01-10
JP6929860B2 (ja) 2021-09-01
PT3405197T (pt) 2023-12-06
TWI841027B (zh) 2024-05-01
US20200397787A1 (en) 2020-12-24
HUE064192T2 (hu) 2024-02-28
KR20250088666A (ko) 2025-06-17
AU2024266962A1 (en) 2024-12-19
JP2019502734A (ja) 2019-01-31
DK3405197T3 (da) 2023-11-27
EP3405197A1 (en) 2018-11-28
SMT202300415T1 (it) 2024-01-10
EP4257205A2 (en) 2023-10-11
FR24C1053I2 (fr) 2025-12-05
CN117159553A (zh) 2023-12-05
RU2018130097A3 (es) 2020-05-25
FIC20240048I1 (fi) 2024-12-19
FR24C1053I1 (fr) 2025-02-21
BR112018014769A2 (pt) 2018-12-11
HUS2400045I1 (hu) 2025-01-28
KR20180102662A (ko) 2018-09-17
RS64798B1 (sr) 2023-11-30
TW201736382A (zh) 2017-10-16
EP4257205A3 (en) 2023-12-20
CN117159554A (zh) 2023-12-05
CN108472297A (zh) 2018-08-31
SG10202006830WA (en) 2020-08-28
AU2017209932A1 (en) 2018-07-05

Similar Documents

Publication Publication Date Title
ZA202500997B (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12021550792A1 (en) 2-(morpholin-4-yl)-1,7-naphthyridines
DOP2019000010A (es) Compuesto (r)-n-(5-cloro-1-(3,3-difluoro-1-(oxetan-3-il)piperidin-4-il)-1h-pirazol-4-il)-4-etoxi-7h-pirrolo[2,3-d]pirimidin-2-amina o sal farmacéuticamente aceptable del mismo
TN2018000043A1 (en) Novel 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as prmt5 inhibitors
PH12016501570A1 (en) Bicyclic aza compounds as muscarinic m1 receptor and/or m4 receptor agonists
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
EA201692003A1 (ru) Макроциклические производные пиримидина
EA201590453A1 (ru) Конденсированные бициклические производные сульфамоила и их применение в качестве лекарственных препаратов для лечения гепатита b
MA38347A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
PH12019502365A1 (en) New bicyclic pyrazole derivatives
EA201692000A1 (ru) Макроциклические производные пиридина
PE20150902A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociado
PE20151748A1 (es) Inhibidores de bace1
MX2018008449A (es) Tratamiento de eccema de las manos.
CY1122837T1 (el) Θεραπεια της γυροειδους αλωπεκιας
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX2021012874A (es) Tratamiento del lupus eritematoso cutaneo.
ECSP19026563A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos
CR20170426A (es) Inhibidores de bace 1
BR112015023560A8 (pt) Novos derivados de acrilamida como agentes antimaláricos
AR107752A1 (es) Inhibidores de bace1
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора